, zl zl
lOM oARc PSD|
zl 3013804
zl zl zl
lOM oARc PSD| 3013804
Chapter 1 Issues for the Practitioner in Drug Therapy
zl zl zl zl zl zl zl zl
MULTIPLE CHOICE zl
1. Nurse practitioner prescriptive authority is regulated by:
zl z l z l zl zl z l
A. The National Council of State Boards of Nursing
zl zl zl zl zl zl zl
B. The U.S. Drug Enforcement Administration
zl zl zl zl
C. The State Board of Nursing for each state
zl zl zl zl zl zl zl
D. The State Board of Pharmacy
zl zl zl zl
ANS: C z l PTS: 1 zl
2. Physician Assistant (PA) prescriptive authority is regulated by:
zl z l z l zl zl zl z l
A. The National Council of State Boards of Nursing
zl zl zl zl zl zl zl
B. The U.S. Drug Enforcement Administration
zl zl zl zl
C. The State Board of Nursing
zl zl zl zl
D. The State Board of Medical Examiners
zl zl zl zl zl
ANS: D z l PTS: 1 zl
3. Clinical judgment in prescribing includes:
zl zl z l zl
A. Factoring in the cost to the patient of the medication prescribed
zl zl zl zl zl zl zl zl zl zl
B. Always prescribing the newest medication available for the disease process
zl zl zl zl zl zl zl zl zl
C. Handing out drug samples to poor patients zl zl zl zl zl zl
D. Prescribing all generic medications to cut costs zl zl zl zl zl z l
ANS: A z l PTS: 1 zl
4. Criteria for choosing an effective drug for a disorder include:
zl zl zl zl zl zl zl zl zl
A. Asking the patient what drug they think would work best for them
zl zl zl zl zl zl zl zl zl zl zl
B. Consulting nationally recognized guidelines for disease management
zl zl z l zl z l z l
C. Prescribing medications that are available as samples before writing a prescription
zl zl zl zl zl zl zl zl zl zl
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for pr
zl zl zl zl zl zl zl z l
escribing
ANS: B z l PTS: 1 zl
5. Nurse practitioner practice may thrive under health-care reform due to:
zl zl zl zl zl zl zl zl zl
A. The demonstrated ability of nurse practitioners to control costs and improve patient out
zl zl zl zl zl zl zl zl zl zl zl z l
comes
B. The fact that nurse practitioners will be able to practice independently
zl zl zl zl zl zl zl zl zl zl
C. The fact that nurse practitioners will have full reimbursement under health-
zl zl zl zl zl zl zl zl zl zl
care reform z l
D. The ability to shift accountability for Medicaid to the state level
zl zl zl zl z l zl zl zl zl zl
ANS: A z l PTS: 1 zl
, zl zl
lOM oARc PSD|
zl 3013804
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
zl zl zl zl zl zl
MULTIPLE CHOICE zl
1. A patient’s nutritional intake and lab work reflects hypoalbuminemia. This is critical to pre
zl zl z l zl zl zl zl zl zl zl zl zl zl
scribing because: z l
A. Distribution of drugs to target tissue may be affected zl zl zl zl zl zl zl zl
B. The solubility of the drug will not match the site of absorption
zl zl zl zl zl zl zl zl zl zl zl
C. There will be less free drug available to generate an effect
zl zl zl zl zl zl zl zl zl zl
D. Drugs bound to albumin are readily excreted by the kidney
zl zl zl zl zl zl zl zl zl
ANS: A z l PTS: 1 zl
2. Drugs that have a significant first-pass effect:
zl zl zl zl zl zl
A. Must be given by the enteral (oral) route only
zl zl zl zl zl zl zl zl
B. Bypass the hepatic circulation zl zl zl
C. Are rapidly metabolized by the liver and may have little if any desired action
zl zl zl zl zl zl z l zl zl zl zl zl zl
D. Are converted by the liver to more active and fat-soluble forms
zl zl zl zl zl zl zl zl zl zl
ANS: C z l PTS: 1 zl
3. The route of excretion of a volatile drug will likely be:
zl zl zl zl zl zl zl zl zl z l
A. The kidneys zl
B. The lungs zl
C. The bile and feces zl zl zl
D. The skin zl
ANS: B z l PTS: 1 zl
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the d zl z l z l zl zl zl zl zl z l zl z l zl zl
rug. Storage reservoirs:
zl zl
A. Assure that the drug will reach its intended target tissue
zl zl zl z l zl zl zl zl zl
B. Are the reason for giving loading doses
zl zl zl zl zl zl
C. Increase the length of time a drug is available and active zl zl zl zl zl zl zl zl zl zl
D. Are most common in collagen tissues
zl zl zl zl zl
ANS: C z l PTS: 1 zl
5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
zl zl zl zl zl zl zl z l zl zl zl zl zl zl
A. Propensity to go to the target receptor zl zl zl zl zl zl
B. Biological half-life z l
C. Pharmacodynamics
D. Safety and side effects zl zl zl
ANS: B z l PTS: 1 zl
6. Azithromycin dosing requires the first day’s dose be twice those of the other 4 days of the pres
zl zl zl zl zl zl zl zl zl zl zl zl zl zl zl zl zl
cription. This is considered a loading dose. A loading dose:
zl zl zl z l zl z l z l zl z l
A. Rapidly achieves drug levels in the therapeutic range zl zl zl zl zl zl zl
B. Requires four to five half-lives to attain zl zl zl zl zl zl
C. Is influenced by renal function
zl zl zl zl
, zl zl
lOM oARc PSD|
zl 3013804
D. Is directly related to the drug circulating to the target tissues
zl zl zl zl zl zl zl zl zl zl
ANS: A z l PTS: z l z l 1
7. The point in time on the drug concentration curve that indicates the first sign of a therapeutic ef
zl zl zl zl zl zl zl zl zl zl zl zl zl zl zl zl zl
fect is the:
zl zl
A. Minimum adverse effect level zl zl zl
B. Peak of action zl zl
C. Onset of action zl zl
D. Therapeutic range z l
ANS: C z l PTS: 1 zl
8. Phenytoin requires a trough level be drawn. Peak and trough levels are done:
zl zl zl zl zl zl zl zl zl zl zl zl
A. When the drug has a wide therapeutic range
zl zl zl zl zl zl zl
B. When the drug will be administered for a short time only
zl zl zl zl zl zl zl zl zl zl
C. When there is a high correlation between the dose and saturation of receptor sites
zl zl zl zl zl zl zl zl zl zl zl zl z l
D. To determine if a drug is in the therapeutic range
zl zl zl zl zl zl zl zl zl
ANS: D z l PTS: 1 zl
9. A laboratory result indicates the peak level for a drug is above the minimum toxic con
zl zl zl zl zl zl zl zl z l zl zl zl zl zl zl
centration. This means that the: zl zl zl zl
A. Concentration will produce therapeutic effects z l z l zl z l
B. Concentration will produce an adverse response zl zl zl zl zl
C. Time between doses must be shortened
zl zl zl zl zl
D. Duration of action of the drug is too long zl zl zl zl zl zl zl zl
ANS: B z l PTS: 1 zl
10. Drugs that are receptor agonists may demonstrate what property?
zl zl zl z l zl zl zl zl
A. Irreversible binding to the drug receptor site zl zl zl zl zl z l
B. Up-regulation with chronic use zl zl zl
C. Desensitization or down-regulation with continuous use zl z l z l zl zl
D. Inverse relationship between drug concentration and drug action
zl zl zl zl zl zl zl
ANS: C z l PTS: 1 zl
11. Drugs that are receptor antagonists, such as beta blockers, may cause:
zl zl zl zl zl zl zl zl zl zl
A. Down-regulation of the drug receptor zl zl z l zl
B. An exaggerated response if abruptly discontinued
zl zl zl zl z l
C. Partial blockade of the effects of agonist drugs
zl zl zl zl zl zl zl
D. An exaggerated response to competitive drug agonists
zl zl zl zl zl zl
ANS: B z l PTS: 1 zl
12. Factors that affect gastric drug absorption include:
zl zl zl zl zl zl
A. Liver enzyme activity zl zl
B. Protein-binding properties of the drug molecule zl zl zl zl z l
C. Lipid solubility of the drug zl zl zl zl
D. Ability to chew and swallow zl zl zl zl
ANS: C z l PTS: 1 zl
lOM oARc PSD|
zl 3013804
zl zl zl
lOM oARc PSD| 3013804
Chapter 1 Issues for the Practitioner in Drug Therapy
zl zl zl zl zl zl zl zl
MULTIPLE CHOICE zl
1. Nurse practitioner prescriptive authority is regulated by:
zl z l z l zl zl z l
A. The National Council of State Boards of Nursing
zl zl zl zl zl zl zl
B. The U.S. Drug Enforcement Administration
zl zl zl zl
C. The State Board of Nursing for each state
zl zl zl zl zl zl zl
D. The State Board of Pharmacy
zl zl zl zl
ANS: C z l PTS: 1 zl
2. Physician Assistant (PA) prescriptive authority is regulated by:
zl z l z l zl zl zl z l
A. The National Council of State Boards of Nursing
zl zl zl zl zl zl zl
B. The U.S. Drug Enforcement Administration
zl zl zl zl
C. The State Board of Nursing
zl zl zl zl
D. The State Board of Medical Examiners
zl zl zl zl zl
ANS: D z l PTS: 1 zl
3. Clinical judgment in prescribing includes:
zl zl z l zl
A. Factoring in the cost to the patient of the medication prescribed
zl zl zl zl zl zl zl zl zl zl
B. Always prescribing the newest medication available for the disease process
zl zl zl zl zl zl zl zl zl
C. Handing out drug samples to poor patients zl zl zl zl zl zl
D. Prescribing all generic medications to cut costs zl zl zl zl zl z l
ANS: A z l PTS: 1 zl
4. Criteria for choosing an effective drug for a disorder include:
zl zl zl zl zl zl zl zl zl
A. Asking the patient what drug they think would work best for them
zl zl zl zl zl zl zl zl zl zl zl
B. Consulting nationally recognized guidelines for disease management
zl zl z l zl z l z l
C. Prescribing medications that are available as samples before writing a prescription
zl zl zl zl zl zl zl zl zl zl
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for pr
zl zl zl zl zl zl zl z l
escribing
ANS: B z l PTS: 1 zl
5. Nurse practitioner practice may thrive under health-care reform due to:
zl zl zl zl zl zl zl zl zl
A. The demonstrated ability of nurse practitioners to control costs and improve patient out
zl zl zl zl zl zl zl zl zl zl zl z l
comes
B. The fact that nurse practitioners will be able to practice independently
zl zl zl zl zl zl zl zl zl zl
C. The fact that nurse practitioners will have full reimbursement under health-
zl zl zl zl zl zl zl zl zl zl
care reform z l
D. The ability to shift accountability for Medicaid to the state level
zl zl zl zl z l zl zl zl zl zl
ANS: A z l PTS: 1 zl
, zl zl
lOM oARc PSD|
zl 3013804
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
zl zl zl zl zl zl
MULTIPLE CHOICE zl
1. A patient’s nutritional intake and lab work reflects hypoalbuminemia. This is critical to pre
zl zl z l zl zl zl zl zl zl zl zl zl zl
scribing because: z l
A. Distribution of drugs to target tissue may be affected zl zl zl zl zl zl zl zl
B. The solubility of the drug will not match the site of absorption
zl zl zl zl zl zl zl zl zl zl zl
C. There will be less free drug available to generate an effect
zl zl zl zl zl zl zl zl zl zl
D. Drugs bound to albumin are readily excreted by the kidney
zl zl zl zl zl zl zl zl zl
ANS: A z l PTS: 1 zl
2. Drugs that have a significant first-pass effect:
zl zl zl zl zl zl
A. Must be given by the enteral (oral) route only
zl zl zl zl zl zl zl zl
B. Bypass the hepatic circulation zl zl zl
C. Are rapidly metabolized by the liver and may have little if any desired action
zl zl zl zl zl zl z l zl zl zl zl zl zl
D. Are converted by the liver to more active and fat-soluble forms
zl zl zl zl zl zl zl zl zl zl
ANS: C z l PTS: 1 zl
3. The route of excretion of a volatile drug will likely be:
zl zl zl zl zl zl zl zl zl z l
A. The kidneys zl
B. The lungs zl
C. The bile and feces zl zl zl
D. The skin zl
ANS: B z l PTS: 1 zl
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the d zl z l z l zl zl zl zl zl z l zl z l zl zl
rug. Storage reservoirs:
zl zl
A. Assure that the drug will reach its intended target tissue
zl zl zl z l zl zl zl zl zl
B. Are the reason for giving loading doses
zl zl zl zl zl zl
C. Increase the length of time a drug is available and active zl zl zl zl zl zl zl zl zl zl
D. Are most common in collagen tissues
zl zl zl zl zl
ANS: C z l PTS: 1 zl
5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
zl zl zl zl zl zl zl z l zl zl zl zl zl zl
A. Propensity to go to the target receptor zl zl zl zl zl zl
B. Biological half-life z l
C. Pharmacodynamics
D. Safety and side effects zl zl zl
ANS: B z l PTS: 1 zl
6. Azithromycin dosing requires the first day’s dose be twice those of the other 4 days of the pres
zl zl zl zl zl zl zl zl zl zl zl zl zl zl zl zl zl
cription. This is considered a loading dose. A loading dose:
zl zl zl z l zl z l z l zl z l
A. Rapidly achieves drug levels in the therapeutic range zl zl zl zl zl zl zl
B. Requires four to five half-lives to attain zl zl zl zl zl zl
C. Is influenced by renal function
zl zl zl zl
, zl zl
lOM oARc PSD|
zl 3013804
D. Is directly related to the drug circulating to the target tissues
zl zl zl zl zl zl zl zl zl zl
ANS: A z l PTS: z l z l 1
7. The point in time on the drug concentration curve that indicates the first sign of a therapeutic ef
zl zl zl zl zl zl zl zl zl zl zl zl zl zl zl zl zl
fect is the:
zl zl
A. Minimum adverse effect level zl zl zl
B. Peak of action zl zl
C. Onset of action zl zl
D. Therapeutic range z l
ANS: C z l PTS: 1 zl
8. Phenytoin requires a trough level be drawn. Peak and trough levels are done:
zl zl zl zl zl zl zl zl zl zl zl zl
A. When the drug has a wide therapeutic range
zl zl zl zl zl zl zl
B. When the drug will be administered for a short time only
zl zl zl zl zl zl zl zl zl zl
C. When there is a high correlation between the dose and saturation of receptor sites
zl zl zl zl zl zl zl zl zl zl zl zl z l
D. To determine if a drug is in the therapeutic range
zl zl zl zl zl zl zl zl zl
ANS: D z l PTS: 1 zl
9. A laboratory result indicates the peak level for a drug is above the minimum toxic con
zl zl zl zl zl zl zl zl z l zl zl zl zl zl zl
centration. This means that the: zl zl zl zl
A. Concentration will produce therapeutic effects z l z l zl z l
B. Concentration will produce an adverse response zl zl zl zl zl
C. Time between doses must be shortened
zl zl zl zl zl
D. Duration of action of the drug is too long zl zl zl zl zl zl zl zl
ANS: B z l PTS: 1 zl
10. Drugs that are receptor agonists may demonstrate what property?
zl zl zl z l zl zl zl zl
A. Irreversible binding to the drug receptor site zl zl zl zl zl z l
B. Up-regulation with chronic use zl zl zl
C. Desensitization or down-regulation with continuous use zl z l z l zl zl
D. Inverse relationship between drug concentration and drug action
zl zl zl zl zl zl zl
ANS: C z l PTS: 1 zl
11. Drugs that are receptor antagonists, such as beta blockers, may cause:
zl zl zl zl zl zl zl zl zl zl
A. Down-regulation of the drug receptor zl zl z l zl
B. An exaggerated response if abruptly discontinued
zl zl zl zl z l
C. Partial blockade of the effects of agonist drugs
zl zl zl zl zl zl zl
D. An exaggerated response to competitive drug agonists
zl zl zl zl zl zl
ANS: B z l PTS: 1 zl
12. Factors that affect gastric drug absorption include:
zl zl zl zl zl zl
A. Liver enzyme activity zl zl
B. Protein-binding properties of the drug molecule zl zl zl zl z l
C. Lipid solubility of the drug zl zl zl zl
D. Ability to chew and swallow zl zl zl zl
ANS: C z l PTS: 1 zl
